 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- | metformin / generics
Clinical, Journal: Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy. (Pubmed Central) - Apr 17, 2019
In patients with T2DM, PF-06291874 significantly lowered HbA1c and glucose, was well tolerated, and had low risk of hypoglycemia. Small, non-dose-related increases in BP, lipids, and hepatic transaminases were observed.
- |||| PF-06291874 / Pfizer
Trial completion: A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin (clinicaltrials.gov) - Sep 16, 2016
P2, N=206, Completed, Sponsor: Pfizer
Small, non-dose-related increases in BP, lipids, and hepatic transaminases were observed. Active, not recruiting --> Completed
- ||| PF-06291874 / Pfizer
Enrollment closed: A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin (clinicaltrials.gov) - Aug 17, 2016
P2, N=200, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| PF-06291874 / Pfizer
Enrollment open: A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin (clinicaltrials.gov) - Oct 22, 2015
P2, N=200, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| PF-06291874 / Pfizer
New P2 trial: A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin (clinicaltrials.gov) - Sep 18, 2015
P2, N=200, Not yet recruiting, Sponsor: Pfizer
- |||| PF-06291874 / Pfizer
Trial completion, Monotherapy: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 21, 2015
P2, N=172, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| PF-06291874 / Pfizer
Enrollment open, Monotherapy: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 8, 2014
P2, N=160, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| PF-06291874 / Pfizer
New P2 trial, Monotherapy: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 26, 2014
P2, N=160, Not yet recruiting, Sponsor: Pfizer
- ||| PF-06291874 / Pfizer
Trial completion: PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) - Mar 17, 2014
P1, N=117, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| PF-06291874 / Pfizer
New P1 trial: PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) - May 15, 2013
P1, N=117, Completed, Sponsor: Pfizer
- PF-06291874 / Pfizer
Trial completion: Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Mar 31, 2013
P1, N=8, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- PF-06291874 / Pfizer
New P1 trial: Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Feb 14, 2013
P1, N=8, Completed, Sponsor: Pfizer
- PF-06291874 / Pfizer
Trial termination: A Single Dose Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Jan 26, 2012
P1, N=9, Terminated, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Terminated; See termination reason in detailed description.
- PF-06291874 / Pfizer
Enrollment change: A Single Dose Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Jan 26, 2012
P1, N=9, Terminated, Sponsor: Pfizer
Recruiting --> Terminated; See termination reason in detailed description. N=16 --> 9
- PF-06291874 / Pfizer
New P1 trial: A Single Dose Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Nov 13, 2011
P1, N=9, Terminated, Sponsor: Pfizer